# Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer

> **NCT03203304** · PHASE1 · TERMINATED · sponsor: **University of Chicago** · enrollment: 14 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03203304
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-25
- **Primary completion:** 2019-03-13
- **Final completion:** 2019-03-13
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Study stopped due to poor accrual.
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03203304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03203304, "Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03203304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*